Dormant HIV Being Flushed Out By Cancer Drug


Advertisement
by Rukmani Krishna on  July 28, 2012 at 3:17 PM AIDS/HIV News
  •   Print
  •   Share
  •   Comments
  •  Text 
Researchers in a new study showed that a drug used to treat certain types of lymphoma was able to dislodge hidden virus in patients receiving treatment for HIV. The researchers are from the University of North Carolina at Chapel Hill found in a new study.
 Dormant HIV Being Flushed Out By Cancer Drug

The existence of persistent reservoirs of dormant HIV in the immune system that are not attacked by anti-AIDS drugs is believed to be a major reason why infection re-emerges once patients stop taking their medication. The disruption and clearance of these reservoirs is critical to finding a cure for AIDS.

Researchers at UNC, working in collaboration with scientists from the Harvard School of Public Health, National Cancer Institute, Merck, and the University of California at San Diego, undertook a series of experiments designed to evaluate the potential of the drug vorinostat, a deacetylase inhibitor that is used to treat some types of lymphoma, to activate and disrupt the dormant virus.

Initially, laboratory experiments measuring active HIV levels in CD4+ T cells, which are specialized white blood cells that the virus uses to replicate, showed that vorinostat unmasked the hidden virus in these cells. Subsequently, vorinostat was administered to eight HIV-infected men who were medically stable on antiretroviral therapy and the levels of active HIV virus were measured and compared to the levels prior to administration.

Those patients receiving vorinostat showed an average 4.5-fold increase in the levels of HIV RNA in CD4+ T cells, evidence that the virus was being unmasked. This is the first published study to show the potential for deacetylase inhibitors to attack latency within dormant virus pools in a translational clinical study.

"This work provides compelling evidence for a new strategy to directly attack and eradicate latent HIV infection," said David Margolis, MD, professor of medicine, microbiology and immunology, and epidemiology at the University of North Carolina at Chapel Hill.

Targeting latency is the first step on a path that may lead to a cure.

"Long-term, widespread use of antiretrovirals has personal and public health consequences, including side effects, financial costs, and community resistance. We must seek other ways to end the epidemic, and this research provides new hope for a strategy to eradicate HIV completely from the body," said Margolis, who led the study.

The study was published in the latest issue of the leading scientific journal, Nature.

Source-ANI
Do you like this Report?
1

 Email Email  RSS Feeds RSS Feeds  Print this page Print  Save this page Save  Link Link  Syndicate Syndicate  Comments Comments 
 
Comment & Contribute
Comments should be on the topic and should not be abusive. Comments are normally moderated and are reviewed after they are posted.
* Your comment can be maximum of 2500 characters

Notify me when reply is posted
I agree to the terms and conditions
  
If you have a question about health related issues, you can now post it in our Ask An Expert section on our community website Medwonders.com and get answers from our panel of experts.
X

Related Links

AIDS/HIV Related News

  • Health News Index
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Archive
Date :
Category :
Keyword :
Quiz on Cancer
Looking for information on cancer? Go through medindia's Cancer quiz.
  • News Quick Links
News Central Health Watch
Latest Health News Health In Focus
News Category (500+) Breaking Health News
Popular News Celebrating Life
Health News and Press Release Medindia - Exclusive
News Photo Gallery India Special
News Video Gallery Lifestyle and Wellness
News From Other Resources
HIV
Complete Medindia Resources
News Categories:  
Senior Health Center